PRESS RELEASES

All Releases
Jul 19, 2016
AUSTIN, Texas, July 19, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the second quarter of 2016.  Net loss in Q2 2016 was $3.0 million, or $0.07 per share, compared to a net loss in Q2 2015 of $3.4 million, or $0.07 per share.
May 19, 2016
- August 5 th is FDA's Tentative Date for Advisory Committee Meeting - - No Change to PDUFA Date - AUSTIN, Texas, May 19, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY
May 11, 2016
AUSTIN, Texas, May 11, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that researchers will present new data around REMOXY's abuse-deterrent properties at the 35 th Annual Scientific Meeting of the American Pain Society (APS), held this year in Austin, TX.
May 05, 2016
AUSTIN, Texas , May 05, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the first quarter of 2016.  Net loss in Q1 2016 was $5.8 million, or $0.13 per share, compared to a net loss in Q1 2015 of $2.6 million, or $0.06 per share.
Apr 12, 2016
- Company Will Host Conference Call on Wednesday, April 13 th , 8:30am EDT - - Guest Speaker Invited to Discuss REMOXY's Target Market - AUSTIN, Texas, April 12, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that the U.S.
Sep 21, 2015
AUSTIN, Texas, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported that the National Institutes of Health (NIH) has awarded the Company a $1.7 million innovation grant. This grant award provides a path forward for the Company to develop a small molecule drug,